In Brief: NDAC meetings
This article was originally published in The Tan Sheet
NDAC meetings: Tentative joint meeting of FDA's Nonprescription Drugs and Dermatologic & Ophthalmic Drugs Advisory Committees scheduled for July 16; topics are still in development. Both committees also are scheduled to meet July 14 and 15. NDAC will meet jointly with the Pulmonary-Allergy Drugs Advisory Committee Sept. 18-19, possibly for reconsideration of the Rx-to-OTC switch of Schering-Plough's Vancenase AQ. Review of the beclomethasone dipropionate nasal spray was postponed last September at the company's request ("The Tan Sheet" Sept. 30, 1996, p. 9). Schering asked for the delay to further analyze its data before presenting before the committee...
You may also be interested in...
Perrigo promotes in pricing, planning
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Combe sells most of its OTC brands